BEUDAMED
    FDA Adverse Event Injury Summary report: N

    SOLETRA

    MDR report key: 3397496 · Received October 9, 2013

    Report

    Report Number
    3007566237-2013-03309
    Event Type
    Injury
    Date Received
    October 9, 2013
    Date of Event
    May 22, 2009
    Report Date
    September 24, 2013
    Manufacturer
    MEDTRONIC NEUROMODULATION
    Product Code
    MRU
    PMA / PMN Number
    H020007
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    TX, US
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 1

    THE ACTUAL EVENT DATES WERE NOT PROVIDED. THIS DATE IS BASED ON THE DATE OF PUBLICATION OF THE ARTICLE. IT WAS NOT POSSIBLE TO ASCERTAIN SPECIFIC DEVICE INFORMATION FROM THE ARTICLE OR TO MATCH THE EVENTS REPORTED WITH PREVIOUSLY REPORTED EVENTS. CONCOMITANT MEDICAL PRODUCTS: PRODUCT ID 7426, SERIAL# (B)(4), IMPLANTED: (B)(6) 2009, EXPLANTED: (B)(6) 2009. PRODUCT TYPE: IMPLANTABLE NEUROSTIMULATOR: PRODUCT ID NEU_UNKNOWN_LEAD, LOT# UNKNOWN. PRODUCT TYPE: LEAD: PRODUCT ID NEU_UNKNOWN_LEAD, LOT# UNKNOWN. PRODUCT TYPE: LEAD. (B)(4).

    Description of Event or Problem · 1

    MARKS, W., BAILEY, L., REED, M., POMYKAL, A., MERCER, M., MACOMBER, D., ACOSTA, F., HONEYCUTT, J. PALLIDAL STIMULATION IN CHILDREN: COMPARISON BETWEEN CEREBRAL PALSY AND DYT1 DYSTONIA. JOURNAL OF CHILD NEUROLOGY. 2013;28(7):840-848. DOI:10.1177/0883073813488674 SUMMARY: THE AUTHORS COMPARED THE OUTCOMES OF 17 CHILDREN AGED 7 TO 15 YEARS WITH DYT1 DYSTONIA OR CEREBRAL PALSY FOLLOWING DEEP BRAIN STIMULATION. WHILE PATIENTS WITH CEREBRAL PALSY PRESENTED WITH SIGNIFICANTLY GREATER MOTOR DISABILITY THAN THE DYT1 COHORT AT BASELINE, BOTH GROUPS DEMONSTRATED IMPROVEMENT AT 1 YEAR (CEREBRAL PALSY ¼ 24%; DYT1 ¼ 6%). THE GROUP AS A WHOLE DEMONSTRATED SIGNIFICANT IMPROVEMENT ON THE BARRY-ALBRIGHT DYSTONIA SCALE ACROSS TIME. GAINS IN MOTOR FUNCTION WERE APPARENT IN BOTH AXIAL AND APPENDICULAR DISTRIBUTIONS INVOLVING BOTH UPPER AND LOWER EXTREMITIES. GAINS ACHIEVED BY 6 MONTHS WERE SUSTAINED IN THE CEREBRAL PALSY GROUP, WHEREAS THE DYT1 GROUP DEMONSTRATED CONTINUED IMPROVEMENT WITH ONGOING PALLIDAL STIMULATION BEYOND 18 MONTHS. YOUNG PATIENTS WITH DYSTONIA DUE TO CEREBRAL PALSY RESPONDED COMPARABLY TO PATIENTS WITH DYT1 DYSTONIA. THE SEVERITY OF MOTOR IMPAIRMENT IN PATIENTS WITH CEREBRAL PALSY AT BASELINE AND FOLLOW-UP RAISES THE ISSUE OF EVEN EARLIER INTERVENTION WITH NEUROMODULATION IN THIS POPULATION TO LIMIT LONG-TERM MOTOR IMPAIRMENTS DUE TO DYSTONIA. REPORTED EVENT: A (B)(^) MALE PATIENT RETURNED TO THE CLINIC NINE DAYS AFTER IMPLANT DUE TO DRAINING FLUID FROM THE OCCIPITAL INCISION. THE FOLLOWING DAY, ON (B)(6) 2009, THE PATIENT HAD SURGERY TO REMOVE THE ENTIRE DBS DUE TO INFECTION. IT WAS NOTED THAT THE CULTURE GREW STAPHYLOCOCCUS AUREUS. THE PATIENT WAS TAKEN BACK TO THE OPERATING ROOM TWELVE DAYS LATER FOR DEBRIDEMENT AND RECLOSURE OF A POOR HEALING SCALP WOUND. THIS EVENT WAS PREVIOUSLY REPORTED IN MANUFACTURING REPORT # 3007566237-2013-02622. ANY ADDITIONAL INFORMATION RECEIVED REGARDING TH IS EVENT WILL BE REPORTED USING THE NEW MANUFACTURING REPORT #.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    513094 SOLETRA IMPLANTED SUBCORTICAL ELECTRICAL STIMULATOR (MOTOR DISORDERS) MRU MEDTRONIC NEUROMODULATION 7426

    Patients

    Seq Age Sex Outcome Treatment
    1 00012 YR Required Intervention